Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model

Journal of Ultrasound in Medicine

Volumn 31, Issue 11, 2012, Pages 1759-1766

  Hoyt, Kenneth ^a   Sorace, Anna ^a   Saini, Reshu ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antibody therapy; Breast cancer; Contrast enhanced ultrasound; Microbubbles; Volumetric imaging

Indexed keywords

ANIMALS; ANTIBODIES; CELL DEATH; CHEMOTHERAPY; DISEASES; PHYSIOLOGICAL MODELS; TUMORS; ULTRASONIC APPLICATIONS; ULTRASONIC IMAGING;

ANTIBODY THERAPY; BREAST CANCER; CONTRAST ENHANCED ULTRASOUND; MICROBUBBLES; VOLUMETRIC IMAGING;

MEDICAL IMAGING;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUOROCARBON; MONOCLONAL ANTIBODY; PERFLUTREN; TRA 8 MONOCLONAL ANTIBODY; TRA-8 MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOGRAPHY; FEMALE; HUMAN; IMMUNOLOGY; METHODOLOGY; MOUSE; NUDE MOUSE; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; FLUOROCARBONS; HUMANS; IMAGING, THREE-DIMENSIONAL; MICE; MICE, NUDE; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 84868108537     PISSN: 02784297     EISSN: 15509613     Source Type: Journal    
DOI: 10.7863/jum.2012.31.11.1759     Document Type: Article

References (30)

1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492-2502.
2. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7:821-830.
3. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308.
4. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4-and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADDdeficient mouse embryonic fibroblasts. J Biol Chem 2000; 275:25065-25068.
5. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J1997; 16:5386-5397.
6. Buchsbaum DJ, Zhou T, Grizzle WE, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9:3731-3741.
7. Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncol 2006; 2:493-508.
8. Kim H, Morgan DE, Zeng H, et al. Breast tumor xenografts: diffusionweighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 2008; 248:844-851.
9. Kim H, Folks KD, Guo L, et al. DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol 2011; 13:94-103.
10. Hoyt K, Warram JM, Umphrey H, et al. Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med 2010; 29:577-585.
11. Lucidarme O, Kono Y, Corbeil J, et al. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 2006; 239:730-739.
12. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256:519-527.
13. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246:508-518.
14. Willmann JK, Cheng Z, Davis C, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008; 249:212-219.
15. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010; 51:433-440.
16. Anderson CR, Hu X, Zhang H, et al. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol 2011; 46:215-224.
17. Forsberg F, Ro RJ, Fox TB, et al. Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: a comparative study. Ultrasonics 2011; 51:382-389.
18. Rychak JJ, Graba J, Cheung AM, et al. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 2007; 6:289-296.
19. Bhayana D, Kim TK, Jang HJ, Burns PN, Wilson SR. Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. AJR Am J Roentgenol 2010; 194:977-983.
20. Fleischer AC, Lyshchik A, Andreotti RF, Hwang M, Jones HW, Fishman DA. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR Am J Roentgenol 2010; 194:343-348.
21. Gauthier TP, Wasan HS, Muhammad A, Owen DR, Leen EL. Assessment of global liver blood flow with quantitative dynamic contrastenhanced ultrasound. J Ultrasound Med 2011; 30:379-385.
22. Goetti R, Reiner CS, Knuth A, et al. Quantitative perfusion analysis of malignant liver tumors: dynamic computed tomography and contrastenhanced ultrasound. Invest Radiol 2012; 47:18-24.
23. Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med 2011; 11:18-24.
24. Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification -preliminary results. Radiology 2011; 258:291-300.
25. Hoyt K, Sorace AG, Saini R. Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound. Invest Radiol 2012; 47:1-8.
26. Feingold S, Gessner R, Guracar IM, Dayton PA. Quantitative volumetric perfusion mapping of the microvasculature using contrast ultrasound. Invest Radiol 2010; 45:669-674.
27. Martincich L, Bertotto I, Montemurro F, et al. Variation of breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally advanced breast cancer. AJR Am J Roentgenol 2011; 196:1214-1218.
28. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66:181-196.
29. Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ. Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol Cancer Res 2011; 9:403-417.
30. Derosier LC, Vickers SM, Zinn KR, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007; 6:3198-3207.